secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-06-01T20:28:49+00:00
Accession:  0001689548-26-000053
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Precision Medicines: Phase 2/3 vormatrigine study fails primary endpoint in focal seizures
--------------------------------------------------------------------------------

- POWER1 study of vormatrigine in focal onset seizures did not meet primary success measure.
- Secondary 50% response rate achieved; higher 30 mg dose showed more pronounced seizure reduction in second half.
- Vormatrigine well-tolerated with <10% adverse event-related discontinuations; ~90% entered open-label extension.
- Company pausing enrollment in POWER2 study to reassess vormatrigine program and potential modifications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/0001689548-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/prax-20260601.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer